Loading...
Please wait, while we are loading the content...
Similar Documents
Le traitement du lymphome de Hodgkin chez l'adulte
| Content Provider | Semantic Scholar |
|---|---|
| Author | Boyer, Marianne Cuerrier, Sophie |
| Copyright Year | 2010 |
| Abstract | Resume Objectif : Determiner les meilleures modalites de traitement du lymphome de Hodgkin. Sources des donnees : Une revue de la litterature scientifique a ete effectuee a l’aide de la base de donnees Pubmed (periode 1990-2010 et mots cles : Hodgkin, adulte). Des references secondaires et tertiaires ont egalement ete consultees. Analyse des donnees : Beaucoup d’etudes sont effectuees aupres de patients atteints du lymphome de Hodgkin. L’ABVD (doxorubicine, bleomycine, vinblastine et dacarbazine) est presentement le traitement standard autant pour les stades localises qu’avances. Il s’est avere au moins aussi efficace que la plupart des autres protocoles etudies tout en etant moins toxique autant a court qu’a long terme. Le seul protocole qui pourrait s’averer superieur a l’ABVD est le BEACOPP (bleomycine, etoposide, doxorubicine, cyclophosphamide, vincristine, procarbazine et prednisone). Cependant, sa toxicite superieure limite son utilisation pour le moment. La radiotherapie est aussi une pierre angulaire du traitement, principalement pour les maladies localisees. Son utilisation lors de maladies avancees est plus controversee. Conclusion : Meme si le lymphome de Hodgkin a un taux de guerison eleve par rapport a d’autres cancers, la gestion des toxicites a long terme, le traitement des rechutes ou le traitement des cas resistants demeurent des defis pour les annees a venir. Abstract Objective: To determine the optimal treatment modalities of Hodgkin’s disease. Data sources: A review of the scientific literature from 1996 to 2006 was done on Pubmed using the following key words : Hodgkin’s, adult. Secondary and tertiary references were also consulted. Data analysis: Many studies have been done in patients with Hodgkin’s disease. ABVD is currently the standard of care for both localized and advanced stages of the disease. It was found to be at least as effective as most protocols while having less long term and short term toxicity. The only protocol that may be superior to ABVD is the BEACOPP protocol (bleomycin, etoposide, doxorubicin, cyclophoshamide, vincristine, procarbazine and prednisone). However, its significant toxicity profile limits its use for the moment. Radiotherapy is also a cornerstone of treatment, mainly for localized disease. The use of radiotherapy in more advanced stages of the disease is controversial. Conclusion: Even though Hodgkin’s disease has a high cure rate as compared to other cancers, the management of long term toxicity, relapses and refractory cases remain challenging. Key words: Hodgkin’s lymphoma, chemotherapy, ABVD, BEACOPP, Stanford V, adverse reactions. |
| File Format | PDF HTM / HTML |
| Volume Number | 43 |
| Alternate Webpage(s) | https://pharmactuel.com/pharmactuel/index.php/pharmactuel/article/download/770/437 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |